Effect of Dapagliflozin on Cause-Specific Mortality in Patients With Heart Failure Across the Spectrum of Ejection Fraction: A Participant-Level Pooled Analysis of DAPA-HF and DELIVER

IMPORTANCE: In 2 trials enrolling patients with heart failure (HF) across the spectrum of ejection fraction (EF), dapagliflozin has been shown to reduce the rate of the composite of worsening HF events or death from cardiovascular (CV) causes. OBJECTIVE: To examine the effects of dapagliflozin on ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Desai, Akshay S., Jhund, Pardeep S., Claggett, Brian L., Vaduganathan, Muthiah, Miao, Zi Michael, Kondo, Toru, Barkoudah, Ebrahim, Brahimi, Abdel, Connolly, Eugene, Finn, Peter, Lang, Ninian N., Mc Causland, Finnian R., McGrath, Martina, Petrie, Mark C., McMurray, John J. V., Solomon, Scott D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531084/
https://www.ncbi.nlm.nih.gov/pubmed/36189985
http://dx.doi.org/10.1001/jamacardio.2022.3736

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531084/
https://www.ncbi.nlm.nih.gov/pubmed/36189985
http://dx.doi.org/10.1001/jamacardio.2022.3736

Ejemplares similares